NHD: Small, illiquid pharma with limited upside vs last 12-month trading range
Intrinsic value VND 69,353 vs market price VND 62,000, implied upside 11.9% (confidence: low).
Business Overview
Công ty Cổ phần Dược phẩm Nam Hà (NHD) is a UPCom-listed pharmaceutical company operating in the domestic pharmaceuticals segment (ICB: Dược phẩm). Public filings show modest scale: reported revenue of VND 1,098.1 bn in 2025 and net profit of VND 51.4 bn in 2025. Total assets expanded to VND 995.7 bn in 2025 from VND 577.9 bn in 2019, indicating balance-sheet growth over the period. The company is tightly held by individuals: the top four shareholders together own ~78% (24.0% + 22.59% + 17.24% + 14.0%), leaving minimal free float and no foreign room (foreign_room 0.0).
Investment Thesis
Intrinsic-value analysis (70% DCF / 30% blended) produces VND 69,353 per share vs a market price of VND 62,000, implying an upside of 11.9% but with low model confidence. The DCF component uses a WACC of 11.1% and terminal growth of 4.0%; the model reports a raw DCF intrinsic of VND 95,338.9 per share before calibration. Key positives: (1) recent revenue and profit show recovery to VND 1,098.1 bn and VND 51.4 bn in 2025, respectively; (2) high measured earnings quality at 90/100 suggests reported earnings are generally reliable; (3) low leverage on-model (net debt ~VND 132.8 bn) relative to asset base of VND 995.7 bn. Key negatives: (1) the stock is illiquid (avg volume 2w = 195 shares) and flagged as "illiquid" in the model, which raises execution risk and increases the bid-ask/market-impact premium required by investors; (2) concentrated individual ownership (~78% by four individuals) and zero foreign room constrain potential demand and liquidity; (3) many standard valuation and ratio fields (P/E, ROE, margins, BVPS) are not available in the dataset, making cross-checks and peer-normalization harder; (4) model confidence is explicitly low, and the intrinsic value has been isotonic-calibrated from a raw DCF higher than the blended outcome, signaling parameter sensitivity. Given the moderate implied upside (11.9%) and elevated execution/liquidity risks, the upside does not sufficiently compensate for the low-confidence inputs.
Valuation Commentary
Blended valuation using a 70% DCF and 30% calibrated peer/PE component; DCF uses a WACC of 11.1% and terminal growth of 4.0%.
- Base free cash flow (model): VND 42.9 bn
- WACC (ke) of 11.1% with beta 0.91 and ERP 4.38%
- Terminal growth rate 4.0% and TV contribution of 51.66% of enterprise value
- Net debt of VND 132.8 bn subtracted from enterprise value
- Isotonic calibration lowered raw DCF (VND 95,338.9) to blended intrinsic VND 69,353
The blended intrinsic value implies 11.9% upside but model confidence is low, primarily due to illiquidity and sensitivity to DCF assumptions. The calibrated intrinsic is materially below the raw DCF, so treat the point estimate as directional rather than precise. We place limited weight on the target until more robust public financial metrics and trading liquidity are available.
Bull vs Bear
- Revenue recovered to VND 1,098.1 bn in 2025 with net profit VND 51.4 bn, supporting cash generation (base FCF VND 42.9 bn).
- High earnings quality score (90/100) suggests reported earnings are reliable and not heavily distorted.
- Low reported net debt (VND 132.8 bn) relative to total assets VND 995.7 bn provides balance-sheet flexibility for modest M&A or working-capital needs.
- Stock is illiquid (avg volume 2w = 195 shares) and flagged as 'illiquid', increasing trading execution risk and widening potential bid-ask spreads.
- Concentrated insider ownership (top four hold ~78%) and zero foreign room limit demand and make free float very thin.
- Key financial ratios (ROE, margins, P/E, P/B) are unavailable, restricting valuation cross-checks and raising model uncertainty.
- Model confidence is low and the raw DCF (VND 95,338.9) had to be isotonic-calibrated down to VND 69,353, indicating sensitivity to assumptions.
Sector Context
The Vietnamese pharmaceuticals sector is fragmented with many small domestic manufacturers and distributors. Regulatory and procurement dynamics (state hospital tendering, private retail chains) can cause volatile sales patterns. VAS accounting and disclosure standards for smaller UPCom issuers can differ in rigor from listed exchanges, so earnings comparability may be impaired. For banks and larger conglomerates in Vietnam, additional context like SBV credit quotas or VAMC bonds matter; for small pharma names the primary local considerations are registration/licenses for products, pricing/tender rules, and distribution channel access. Within the peer set (351 companies), the median implied upside is 12.1%, so NHD's 11.9% sits very close to sector median but with notably lower liquidity and model confidence than many peers.
Risk Factors
- Illiquidity: average volume over 2 weeks is only 195 shares and the model flags the stock as 'illiquid', increasing market-impact costs.
- Concentrated ownership: four individuals control ~78% of shares, raising the risk of limited float and potential insider-driven supply shocks.
- Zero foreign ownership room (foreign_room 0.0) prevents incremental foreign demand, which can cap rerating potential.
- Data gaps: absence of published ratios (ROE, margins, P/E, P/B) reduces transparency and makes valuation less robust.
- Model sensitivity: blended intrinsic value derives heavily from a DCF that was calibrated down from a higher raw DCF, indicating sensitivity to WACC and terminal-growth inputs.
- Small-company operational risks: product registration, changes in tender/procurement rules, and dependence on a small number of customers/distributors can materially affect revenue.
Catalysts
- Improved liquidity or an increase in free float (e.g., a secondary offering or insider reduction) that could allow foreign ownership and broaden the investor base.
- Publication of fuller financials or independent audits providing the standard ratios (ROE, margins, P/E) to reduce valuation uncertainty.
- Better-than-expected top-line growth or margin expansion in quarterly/annual results that supports a higher DCF outcome.
- Any regulatory approvals or new product launches that materially increase addressable market or pricing power.
Forensic Assessment
No M-Score is available and the forensic dataset shows no red flags; the principal forensic signal is the high earnings-quality score of 90/100, which supports reported profitability. However, UPCom reporting and the absence of several standard ratios warrant cautious interpretation. Because M-Score and explicit forensic indicators are null, there is no documented manipulation signal in the provided data, but disclosure and audit quality remain relevant monitoring points.
Track Record
Model history is limited: one year of coverage (first_year 2026, last_year 2026) with average past implied upside of 11.86%. Hit rate is not available, so historical predictive skill cannot be verified. Given the short track record and low model confidence, place limited weight on back-test statistics.
Written by a language model on 2026-08-10 from this page’s own model outputs and financial statements, and may quote figures from that date. Descriptive analysis, not investment advice — no buy, sell or hold recommendation is given or implied.